147 related articles for article (PubMed ID: 36059151)
1. Single-cell transcriptomics uncovers cellular architecture and developmental trajectories in hepatoblastoma.
Huang H; Wu L; Lu L; Zhang Z; Qiu B; Mo J; Luo Y; Xi Z; Feng M; Wan P; Zhu J; Yu D; Wu W; Tan K; Liu J; Sheng Q; Xu T; Huang J; Lv Z; Tang Y; Xia Q
Hepatology; 2023 Jun; 77(6):1911-1928. PubMed ID: 36059151
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
[TBL] [Abstract][Full Text] [Related]
3. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
Clavería-Cabello A; Herranz JM; Latasa MU; Arechederra M; Uriarte I; Pineda-Lucena A; Prosper F; Berraondo P; Alonso C; Sangro B; García Marin JJ; Martinez-Chantar ML; Ciordia S; Corrales FJ; Francalanci P; Alaggio R; Zucman-Rossi J; Indersie E; Cairo S; Domingo-Sàbat M; Zanatto L; Sancho-Bru P; Armengol C; Berasain C; Fernandez-Barrena MG; Avila MA
J Hepatol; 2023 Oct; 79(4):989-1005. PubMed ID: 37302584
[TBL] [Abstract][Full Text] [Related]
4. Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.
Beck A; Eberherr C; Hagemann M; Cairo S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
Cancer Biol Ther; 2016 Nov; 17(11):1168-1176. PubMed ID: 27635950
[TBL] [Abstract][Full Text] [Related]
5. The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma.
Lieber J; Armeanu-Ebinger S; Fuchs J
Int J Mol Sci; 2015 Feb; 16(2):4190-208. PubMed ID: 25690034
[TBL] [Abstract][Full Text] [Related]
6. Molecular networks of hepatoblastoma predisposition and oncogenesis in Beckwith-Wiedemann syndrome.
Sobel Naveh NS; Traxler EM; Duffy KA; Kalish JM
Hepatol Commun; 2022 Aug; 6(8):2132-2146. PubMed ID: 35507738
[TBL] [Abstract][Full Text] [Related]
7. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
8. DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer.
Wang Q; Liang N; Yang T; Li Y; Li J; Huang Q; Wu C; Sun L; Zhou X; Cheng X; Zhao L; Wang G; Chen Z; He X; Liu C
J Hepatol; 2021 Nov; 75(5):1142-1153. PubMed ID: 34217777
[TBL] [Abstract][Full Text] [Related]
9. The Role of N
Auld FM; Sergi CM; Leng R; Shen F
Cells; 2022 Apr; 11(9):. PubMed ID: 35563821
[TBL] [Abstract][Full Text] [Related]
10. New insights into diagnosis and therapeutic options for proliferative hepatoblastoma.
Hooks KB; Audoux J; Fazli H; Lesjean S; Ernault T; Dugot-Senant N; Leste-Lasserre T; Hagedorn M; Rousseau B; Danet C; Branchereau S; Brugières L; Taque S; Guettier C; Fabre M; Rullier A; Buendia MA; Commes T; Grosset CF; Raymond AA
Hepatology; 2018 Jul; 68(1):89-102. PubMed ID: 29152775
[TBL] [Abstract][Full Text] [Related]
11. Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: a report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94.
Fuchs J; Bode U; von Schweinitz D; Weinel P; Erttmann R; Harms D; Mildenberger H
Klin Padiatr; 1999; 211(4):305-9. PubMed ID: 10472567
[TBL] [Abstract][Full Text] [Related]
12. β-Catenin mutations as determinants of hepatoblastoma phenotypes in mice.
Zhang W; Meyfeldt J; Wang H; Kulkarni S; Lu J; Mandel JA; Marburger B; Liu Y; Gorka JE; Ranganathan S; Prochownik EV
J Biol Chem; 2019 Nov; 294(46):17524-17542. PubMed ID: 31597698
[TBL] [Abstract][Full Text] [Related]
13. Potential therapies for residual hepatoblastoma following incomplete ablation treatment in a nude mouse subcutaneous xenograft model based on lncRNA and mRNA expression profiles.
Wang XD; Peng JB; Zhou CY; Que Q; Li HY; He Y; Yang H
Oncol Rep; 2020 Jun; 43(6):1915-1927. PubMed ID: 32186781
[TBL] [Abstract][Full Text] [Related]
14. De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity.
Moosavi SH; Eide PW; Eilertsen IA; Brunsell TH; Berg KCG; Røsok BI; Brudvik KW; Bjørnbeth BA; Guren MG; Nesbakken A; Lothe RA; Sveen A
Genome Med; 2021 Sep; 13(1):143. PubMed ID: 34470666
[TBL] [Abstract][Full Text] [Related]
15. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
[TBL] [Abstract][Full Text] [Related]
16. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
[TBL] [Abstract][Full Text] [Related]
17. YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte-Like Cells.
Smith JL; Rodríguez TC; Mou H; Kwan SY; Pratt H; Zhang XO; Cao Y; Liang S; Ozata DM; Yu T; Yin Q; Hazeltine M; Weng Z; Sontheimer EJ; Xue W
Hepatology; 2021 Mar; 73(3):1011-1027. PubMed ID: 32452550
[TBL] [Abstract][Full Text] [Related]
18. Alternative Splicing of lncRNAs From SNHG Family Alters snoRNA Expression and Induces Chemoresistance in Hepatoblastoma.
Zhen N; Zhu J; Mao S; Zhang Q; Gu S; Ma J; Zhang Y; Yin M; Li H; Huang N; Wu H; Sun F; Ying B; Zhou L; Pan Q
Cell Mol Gastroenterol Hepatol; 2023; 16(5):735-755. PubMed ID: 37478905
[TBL] [Abstract][Full Text] [Related]
19. Cytomorphology of hepatoblastoma with histological correlation and role of SALL4 immunocytochemistry in its diagnosis, subtyping, and prognostication.
Nakra T; Roy M; Yadav R; Agarwala S; Jassim M; Khanna G; Das P; Jain D; Mathur SR; Iyer VK
Cancer Cytopathol; 2020 Mar; 128(3):190-200. PubMed ID: 31880869
[TBL] [Abstract][Full Text] [Related]
20. MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma.
Woodfield SE; Shi Y; Patel RH; Chen Z; Shah AP; Srivastava RK; Whitlock RS; Ibarra AM; Larson SR; Sarabia SF; Badachhape A; Starosolski Z; Ghaghada KB; Sumazin P; Annis DA; López-Terrada D; Vasudevan SA
Sci Rep; 2021 Feb; 11(1):2967. PubMed ID: 33536467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
